Crispr Therapeutics Viking Therapeutics: 2026 Stock Showdown
As biotech investors look to 2026, crispr therapeutics viking therapeutics presents two distinct paths: gene editing ...
Obesity Treatments
2 articles
This Obesity Drug Stock Surges 60% on Phase 3 News
A notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...